Blog

Miguel Bronchud: Preventing cancer-related deaths with molecular cancer signals circulating in blood

Miguel Bronchud/LinkedIn

Jan 9, 2025, 15:41

Miguel Bronchud: Preventing cancer-related deaths with molecular cancer signals circulating in blood

Miguel Bronchud, Co-Founder and Advisory Board at Regenerative Medicine Solutions shared on LinkedIn:

“Imagine one could detect cancer before it becomes malignant enough to kill; and with a minimally invasive test (blood test or other), or with an imaging device capable of detecting key mutations or aberrant chromosomes?

Ideally, detection of cancer before it becomes ‘invisible to our own immune systems’ – for example, by reactivating encrypted feto maternal tolerance immune regulators, could give us a wonderful therapeutic opportunity to inhibit or even to avoid local tissue invasions, metastatic spread by lymph nodes or blood, or cancer progression.

Researchers at Stanford University, CA, reviewed the evidence recently-Breakthroughs in laboratory and data science are increasing interest in blood tests to screen for cancer, with colorectal cancer screening at the forefront (see references below ). These emerging tests should be judged according to classic criteria the detection of treatable latent disease, improved outcomes compared with no screening, safety, acceptability, and cost-effectiveness relative to alternative options.

Developers of novel colorectal cancer screening blood tests are first seeking regulatory approval in the USA, with plans to expand outside the USA in the future.

See:
1. Chung, DC ∙ Gray, 2nd, DM ∙ Singh, H ∙ et al. A cell-free DNA blood-based test for colorectal cancer screening N Engl J Med. 2024; 390:973-983
2. Bresalier, RS ∙ Senore, C ∙ Young, GP ∙ et al. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles Gut. 2023; 72:1904-1918
3. Ladabaum, U ∙ Mannalithara, A ∙ Weng, Y ∙ et al. Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (liquid biopsy) vs fecal tests or colonoscopy Gastroenterology. 2024; 167:378-391.”

Can molecular cancer signals circulating in blood help us prevent cancer-related deaths? – The Lancet

Authors: Uri Ladabaum, Jason A Dominitz, David Lieberman, Robert E Schoen

Miguel Bronchud: Preventing cancer-related deaths with molecular cancer signals circulating in blood